FRAXA Contributes $10,000 to NIH grant to Seaside Therapeutics

Randall Carpenter, MD, at Massachusetts Institute of Technology, FRAXA research grantwith Mark Bear, PhD, MIT

Co-Investigator (2007)

 

Clinical development of mGluR5 Antagonists to treat Fragile X syndrome and Autism

Seaside Therapeutics received a major grant from the NIH, with additional funding from FRAXA and Cure Autism Now (CAN) to develop STX107, a selective mGluR5 antagonist, as a treatment for fragile X.

Unfortunately Seaside has since discontinued development of STX107.